William Mezzanotte
Technik-/Wissenschafts-/F&E-Leiter bei CSL LIMITED
Profil
Derzeit ist William Mezzanotte Chief Medical Officer, EVP & Head-R&D bei CSL Ltd. Dr. Mezzanotte ist außerdem Mitglied des Vorstands von BELLUS Health, Inc. und des University City Science Center. Zuvor war Dr. Mezzanotte Vice President & Head-Respiratory & Inflammation bei AstraZeneca Plc und Senior Vice President & Head-Therapeutic Area bei C.H. Boehringer Sohn AG & Co. KG. William Mezzanotte erhielt einen Bachelor-Abschluss von der Villanova University, einen Doktortitel von der University of Pennsylvania und einen Master-Abschluss von der Johns Hopkins University.
Aktive Positionen von William Mezzanotte
| Unternehmen | Position | Beginn |
|---|---|---|
| CSL LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2018 |
University City Science Center
 University City Science Center Investment Trusts/Mutual FundsMiscellaneous University City Science Center provides physical space, resources and other support to the community. The company was founded in 1963 and is headquartered in Philadelphia, PA. | Direktor/Vorstandsmitglied | 19.06.2020 |
Ehemalige bekannte Positionen von William Mezzanotte
| Unternehmen | Position | Ende |
|---|---|---|
| BELLUS HEALTH | Direktor/Vorstandsmitglied | 01.01.2023 |
C.H. Boehringer Sohn AG & Co. KG
 C.H. Boehringer Sohn AG & Co. KG Pharmaceuticals: MajorHealth Technology C.H. Boehringer Sohn AG & Co. KG operates as a holding company, with interests in the manufacturing of pharmaceutical products. It offers prescription drugs for the treatment of human respiratory, cardiovascular, gastrointestinal, and central nervous system diseases, including human immunodeficiency virus infection and cancer. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Corporate Officer/Principal | 01.04.2017 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01.03.2015 |
CSL Behring LLC
 CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von William Mezzanotte
| Villanova University | Undergraduate Degree |
| University of Pennsylvania | Doctorate Degree |
| The Johns Hopkins University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| CSL LIMITED | Health Technology |
| Private Unternehmen | 4 |
|---|---|
C.H. Boehringer Sohn AG & Co. KG
C.H. Boehringer Sohn AG & Co. KG Pharmaceuticals: MajorHealth Technology C.H. Boehringer Sohn AG & Co. KG operates as a holding company, with interests in the manufacturing of pharmaceutical products. It offers prescription drugs for the treatment of human respiratory, cardiovascular, gastrointestinal, and central nervous system diseases, including human immunodeficiency virus infection and cancer. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Health Technology |
University City Science Center
University City Science Center Investment Trusts/Mutual FundsMiscellaneous University City Science Center provides physical space, resources and other support to the community. The company was founded in 1963 and is headquartered in Philadelphia, PA. | Miscellaneous |
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
CSL Behring LLC
CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA. | Health Technology |
